Effects of ACE inhibition on endothelial progenitor cell mobilization and prognosis after acute myocardial infarction in type 2 diabetic patients

OBJECTIVE: We aimed to assess the chemotactic response of endothelial progenitor cells to angiotensin-converting enzyme inhibitors in T2DM patients after acute myocardial infarction, as well as the associated prognosis. METHODS: Sixty-eight T2DM patients with acute myocardial infarction were randomized to either receive or not receive daily oral perindopril 4 mg, and 36 non-diabetic patients with acute myocardial infarction were enrolled as controls. The numbers of circulating CD45−/low+CD34+CD133+KDR+ endothelial progenitor cells, as well as the stromal cell-derived factor-α and high-sensitivity C reactive protein levels, were measured before acute percutaneous coronary intervention and on days 1, 3, 5, 7, 14, and 28 after percutaneous coronary intervention. Patients were followed up for 6 months. Chinese Clinical Trial Registry: ChiCTR-TRC-12002599. RESULTS: T2DM patients had lower circulating endothelial progenitor cell counts, decreased plasma vascular endothelial growth factor and α levels, and higher plasma high-sensitivity C reactive protein levels compared with non-diabetic controls. After receiving perindopril, the number of circulating endothelial progenitor cells increased from day 3 to 7, as did the plasma levels of vascular endothelial growth factor and stromal cell-derived factor-α, compared with the levels in T2DM controls. Plasma high-sensitivity C reactive protein levels in the treated group decreased to the same levels as those in non-diabetic controls. Furthermore, compared with T2DM controls, the perindopril-treated T2DM patients had lower cardiovascular mortality and occurrence of heart failure symptoms (p<0.05) and better left ventricle function (p<0.01). CONCLUSIONS: The use of angiotensin-converting enzyme inhibitors represents a novel approach for improving cardiovascular repair after acute myocardial infarction in T2DM patients. .

Treatment of thirty primary hypothyroidism patients by fuzheng fujia mixture / 中国中西医结合杂志

<p><b>OBJECTIVE</b>To observe the clinical efficacy of treating primary hypothyroidism by Fuzheng Fujia Mixture (FFM) with formula composing principles of warming and tonifying Pi and Shen, and eliminating blood stasis and removing turbid substances.</p><p><b>METHODS</b>Totally 60 patients with primary hypothyroidism were randomly assigned to the treated group and the control group, 30 in each group. All were treated by Levothyroxine Sodium Tablet (LST) as routines. Those in the treated group took FFM additionally, 3 times daily, one month as 1 therapeutic course. The therapeutic efficacy was assessed after three therapeutic courses.</p><p><b>RESULTS</b>After treatment the symptom scores were significantly reduced in the two groups (P < 0.05). The decrement was larger in the treated group than in the control group (P < 0.05). The dose of LST was significantly lower in the treated group than in the control group (P < 0.05). The blood lipids levels were significantly reduced in the two groups after treatment (P < 0.05). The decrement was significantly larger in the treated group than in the control group (P < 0.05).</p><p><b>CONCLUSION</b>FFM could obviously improve the symptoms of hypothyroidism patients, reduce the replacement dose of thyroid hormone, and lower the blood lipids levels.</p>